Free Trial
→ The SpaceX supplier that shipped 5 billion chips to Starlink (From Weiss Ratings) (Ad)tc pixel Free TRAX Stock Alerts

First Tracks Biotherapeutics (TRAX) Competitors

$17.06 -0.12 (-0.70%)
As of 04:00 PM Eastern
Compare

TRAX vs. DFTX, HYPD, LIAN, PHXM, and KLDO

Should you buy First Tracks Biotherapeutics stock or one of its competitors? MarketBeat compares First Tracks Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with First Tracks Biotherapeutics include Definium Therapeutics (DFTX), Hyperion DeFi (HYPD), LianBio (LIAN), PHAXIAM Therapeutics (PHXM), and Kaleido Biosciences (KLDO). These companies are all part of the "biotechnology" industry.

How does First Tracks Biotherapeutics compare to Definium Therapeutics?

First Tracks Biotherapeutics (NASDAQ:TRAX) and Definium Therapeutics (NASDAQ:DFTX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

In the previous week, Definium Therapeutics had 5 more articles in the media than First Tracks Biotherapeutics. MarketBeat recorded 7 mentions for Definium Therapeutics and 2 mentions for First Tracks Biotherapeutics. First Tracks Biotherapeutics' average media sentiment score of 0.00 beat Definium Therapeutics' score of -0.08 indicating that First Tracks Biotherapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
First Tracks Biotherapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Definium Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
First Tracks BiotherapeuticsN/AN/AN/AN/AN/A
Definium TherapeuticsN/AN/A-$183.79M-$2.49N/A

27.9% of Definium Therapeutics shares are held by institutional investors. 2.3% of Definium Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

First Tracks Biotherapeutics' return on equity of 0.00% beat Definium Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
First Tracks BiotherapeuticsN/A N/A N/A
Definium Therapeutics N/A -100.30%-69.22%

First Tracks Biotherapeutics presently has a consensus price target of $39.43, suggesting a potential upside of 131.12%. Definium Therapeutics has a consensus price target of $37.92, suggesting a potential upside of 65.75%. Given First Tracks Biotherapeutics' higher probable upside, analysts clearly believe First Tracks Biotherapeutics is more favorable than Definium Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
First Tracks Biotherapeutics
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.00
Definium Therapeutics
1 Sell rating(s)
0 Hold rating(s)
12 Buy rating(s)
2 Strong Buy rating(s)
3.00

Summary

Definium Therapeutics beats First Tracks Biotherapeutics on 5 of the 9 factors compared between the two stocks.

How does First Tracks Biotherapeutics compare to Hyperion DeFi?

Hyperion DeFi (NASDAQ:HYPD) and First Tracks Biotherapeutics (NASDAQ:TRAX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Hyperion DeFi currently has a consensus target price of $5.88, suggesting a potential upside of 58.78%. First Tracks Biotherapeutics has a consensus target price of $39.43, suggesting a potential upside of 131.12%. Given First Tracks Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe First Tracks Biotherapeutics is more favorable than Hyperion DeFi.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hyperion DeFi
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.25
First Tracks Biotherapeutics
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.00

First Tracks Biotherapeutics' return on equity of 0.00% beat Hyperion DeFi's return on equity.

Company Net Margins Return on Equity Return on Assets
Hyperion DeFiN/A -91.59% -73.08%
First Tracks Biotherapeutics N/A N/A N/A

First Tracks Biotherapeutics has lower revenue, but higher earnings than Hyperion DeFi.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hyperion DeFi$810K69.25-$45.31M-$9.95N/A
First Tracks BiotherapeuticsN/AN/AN/AN/AN/A

In the previous week, First Tracks Biotherapeutics had 1 more articles in the media than Hyperion DeFi. MarketBeat recorded 2 mentions for First Tracks Biotherapeutics and 1 mentions for Hyperion DeFi. Hyperion DeFi's average media sentiment score of 0.54 beat First Tracks Biotherapeutics' score of 0.00 indicating that Hyperion DeFi is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Hyperion DeFi
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
First Tracks Biotherapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

25.8% of Hyperion DeFi shares are held by institutional investors. 7.5% of Hyperion DeFi shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

First Tracks Biotherapeutics beats Hyperion DeFi on 6 of the 10 factors compared between the two stocks.

How does First Tracks Biotherapeutics compare to LianBio?

First Tracks Biotherapeutics (NASDAQ:TRAX) and LianBio (NASDAQ:LIAN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

74.8% of LianBio shares are held by institutional investors. 7.6% of LianBio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

First Tracks Biotherapeutics presently has a consensus target price of $39.43, indicating a potential upside of 131.12%. Given First Tracks Biotherapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe First Tracks Biotherapeutics is more favorable than LianBio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
First Tracks Biotherapeutics
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.00
LianBio
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

First Tracks Biotherapeutics' return on equity of 0.00% beat LianBio's return on equity.

Company Net Margins Return on Equity Return on Assets
First Tracks BiotherapeuticsN/A N/A N/A
LianBio N/A -33.17%-30.19%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
First Tracks BiotherapeuticsN/AN/AN/AN/AN/A
LianBioN/AN/A-$110.29M-$0.81N/A

In the previous week, First Tracks Biotherapeutics had 2 more articles in the media than LianBio. MarketBeat recorded 2 mentions for First Tracks Biotherapeutics and 0 mentions for LianBio. First Tracks Biotherapeutics' average media sentiment score of 0.00 equaled LianBio'saverage media sentiment score.

Company Overall Sentiment
First Tracks Biotherapeutics Neutral
LianBio Neutral

Summary

First Tracks Biotherapeutics beats LianBio on 7 of the 9 factors compared between the two stocks.

How does First Tracks Biotherapeutics compare to PHAXIAM Therapeutics?

PHAXIAM Therapeutics (NASDAQ:PHXM) and First Tracks Biotherapeutics (NASDAQ:TRAX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

First Tracks Biotherapeutics has a consensus target price of $39.43, suggesting a potential upside of 131.12%. Given First Tracks Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe First Tracks Biotherapeutics is more favorable than PHAXIAM Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PHAXIAM Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
First Tracks Biotherapeutics
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.00

Company Net Margins Return on Equity Return on Assets
PHAXIAM TherapeuticsN/A N/A N/A
First Tracks Biotherapeutics N/A N/A N/A

In the previous week, First Tracks Biotherapeutics had 2 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 2 mentions for First Tracks Biotherapeutics and 0 mentions for PHAXIAM Therapeutics. PHAXIAM Therapeutics' average media sentiment score of 0.00 equaled First Tracks Biotherapeutics'average media sentiment score.

Company Overall Sentiment
PHAXIAM Therapeutics Neutral
First Tracks Biotherapeutics Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PHAXIAM TherapeuticsN/AN/A-$240KN/AN/A
First Tracks BiotherapeuticsN/AN/AN/AN/AN/A

0.4% of PHAXIAM Therapeutics shares are held by institutional investors. 1.9% of PHAXIAM Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

First Tracks Biotherapeutics beats PHAXIAM Therapeutics on 5 of the 7 factors compared between the two stocks.

How does First Tracks Biotherapeutics compare to Kaleido Biosciences?

Kaleido Biosciences (NASDAQ:KLDO) and First Tracks Biotherapeutics (NASDAQ:TRAX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

First Tracks Biotherapeutics has lower revenue, but higher earnings than Kaleido Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kaleido Biosciences$1.10M0.00-$95.48M-$2.24N/A
First Tracks BiotherapeuticsN/AN/AN/AN/AN/A

First Tracks Biotherapeutics has a consensus target price of $39.43, suggesting a potential upside of 131.12%. Given First Tracks Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe First Tracks Biotherapeutics is more favorable than Kaleido Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kaleido Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
First Tracks Biotherapeutics
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.00

81.6% of Kaleido Biosciences shares are held by institutional investors. 9.0% of Kaleido Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Kaleido BiosciencesN/A N/A N/A
First Tracks Biotherapeutics N/A N/A N/A

In the previous week, First Tracks Biotherapeutics had 2 more articles in the media than Kaleido Biosciences. MarketBeat recorded 2 mentions for First Tracks Biotherapeutics and 0 mentions for Kaleido Biosciences. Kaleido Biosciences' average media sentiment score of 0.00 equaled First Tracks Biotherapeutics'average media sentiment score.

Company Overall Sentiment
Kaleido Biosciences Neutral
First Tracks Biotherapeutics Neutral

Summary

First Tracks Biotherapeutics beats Kaleido Biosciences on 5 of the 8 factors compared between the two stocks.

Get First Tracks Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TRAX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TRAX vs. The Competition

Export
MetricFirst Tracks BiotherapeuticsBiotechnology IndustryMedical SectorNASDAQ Exchange
Market Cap$595.26M$473.53M$6.38B$12.47B
Dividend YieldN/A3.86%2.76%5.28%
P/E RatioN/A3.9420.8825.82
Price / SalesN/A7,071.68548.4386.19
Price / CashN/A13.1343.4956.67
Price / BookN/A84.8310.367.15
Net IncomeN/A-$96.07M$3.56B$335.69M
7 Day Performance2.40%0.46%4.45%4.51%
1 Month Performance-6.06%0.99%1.86%3.09%
1 Year PerformanceN/A64.87%34.79%37.67%

First Tracks Biotherapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TRAX
First Tracks Biotherapeutics
N/A$17.06
-0.7%		$39.43
+131.1%		N/A$595.26MN/AN/AN/A
DFTX
Definium Therapeutics
2.9761 of 5 stars		$22.50
flat		$37.92
+68.5%		+208.2%$2.24BN/AN/A40
HYPD
Hyperion DeFi
3.033 of 5 stars		$3.62
flat		$5.88
+62.3%		+104.5%$54.87M$810KN/A40
LIAN
LianBio
N/A$0.11
+0.1%		N/A-69.4%$11.91MN/AN/A110
PHXM
PHAXIAM Therapeutics
N/A$3.10
flat		N/AN/A$10.58MN/AN/A49

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TRAX) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
I was right about SpaceX
Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...
Brownstone Research | Sponsoredtc pixel
Gold surged 600 dollars last time this indicator peaked
The Buffett Indicator has predicted every major gold bull run this century - 2000, 2008, and 2020, when gold s...
Porter & Company | Sponsoredtc pixel
Elon Confirms SpaceX IPO For 6/12 [Act Now!]
Elon Musk has confirmed SpaceX will IPO on Friday, June 12, 2026, at a valuation of up to $2 trillion - potent...
Paradigm Press | Sponsoredtc pixel
The digital asset institutions are buying before headlines hit
JPMorgan is processing $2 billion a day through new digital rails. BlackRock's tokenized fund crossed $2.8 bil...
Awesomely, LLC | Sponsoredtc pixel
I was right about SpaceX. Now here's the part that matters
Goldman Sachs and JP Morgan have already been tied to allocations surrounding the SpaceX deal. When the bigges...
The Oxford Club | Sponsoredtc pixel